Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Daiichi Sankyo Co., Ltd. - Sponsored ADR stock logo
DSNKY
Daiichi Sankyo
$22.03
+0.6%
$24.34
$20.92
$42.48
$41.49BN/A219,220 shs179,839 shs
MLCPF
Medipharm Labs
$0.05
+3.1%
$0.06
$2.57
$2.57
N/AN/A181,345 shs38,998 shs
Ono Pharmaceutical Co., Ltd. stock logo
OPHLY
Ono Pharmaceutical
$3.58
+0.3%
$3.53
$3.21
$5.20
N/AN/A348,565 shs132,014 shs
ePlus inc. stock logo
PLUS
ePlus
$70.27
-1.3%
$69.58
$53.83
$106.98
$1.89B1.14220,543 shs131,534 shs
WDEXF
OTCMKTS:WDEXF
$0.04
-15.5%
$0.04
$0.02
$0.16
N/AN/A20,945 shs64,100 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Daiichi Sankyo Co., Ltd. - Sponsored ADR stock logo
DSNKY
Daiichi Sankyo
+0.59%-0.99%-11.70%+0.69%-40.30%
MLCPF
Medipharm Labs
+0.10%+0.61%-13.09%-9.45%-2.92%
Ono Pharmaceutical Co., Ltd. stock logo
OPHLY
Ono Pharmaceutical
+0.28%+1.70%-1.38%-9.14%-20.03%
ePlus inc. stock logo
PLUS
ePlus
-1.33%-3.02%-1.95%+20.68%-3.20%
WDEXF
OTCMKTS:WDEXF
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Daiichi Sankyo Co., Ltd. - Sponsored ADR stock logo
DSNKY
Daiichi Sankyo
N/AN/AN/AN/AN/AN/AN/AN/A
MLCPF
Medipharm Labs
N/AN/AN/AN/AN/AN/AN/AN/A
Ono Pharmaceutical Co., Ltd. stock logo
OPHLY
Ono Pharmaceutical
N/AN/AN/AN/AN/AN/AN/AN/A
ePlus inc. stock logo
PLUS
ePlus
2.9731 of 5 stars
0.04.00.03.62.81.71.9
WDEXF
OTCMKTS:WDEXF
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Daiichi Sankyo Co., Ltd. - Sponsored ADR stock logo
DSNKY
Daiichi Sankyo
4.00
Strong BuyN/AN/A
MLCPF
Medipharm Labs
0.00
N/AN/AN/A
Ono Pharmaceutical Co., Ltd. stock logo
OPHLY
Ono Pharmaceutical
0.00
N/AN/AN/A
ePlus inc. stock logo
PLUS
ePlus
0.00
N/AN/AN/A
WDEXF
OTCMKTS:WDEXF
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PLUS, DSNKY, MLCPF, OPHLY, and WDEXF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/6/2025
Daiichi Sankyo Co., Ltd. - Sponsored ADR stock logo
DSNKY
Daiichi Sankyo
Nomura Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Daiichi Sankyo Co., Ltd. - Sponsored ADR stock logo
DSNKY
Daiichi Sankyo
$12.39B3.37$1.26 per share17.45$5.61 per share3.93
MLCPF
Medipharm Labs
N/AN/AN/AN/AN/AN/A
Ono Pharmaceutical Co., Ltd. stock logo
OPHLY
Ono Pharmaceutical
N/AN/AN/AN/AN/AN/A
ePlus inc. stock logo
PLUS
ePlus
$2.07B0.90$5.10 per share13.78$36.73 per share1.91
WDEXF
OTCMKTS:WDEXF
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Daiichi Sankyo Co., Ltd. - Sponsored ADR stock logo
DSNKY
Daiichi Sankyo
$1.95B$1.0321.3920.211.1215.65%17.92%8.61%7/29/2025 (Estimated)
MLCPF
Medipharm Labs
N/AN/A0.00N/AN/AN/AN/AN/A
Ono Pharmaceutical Co., Ltd. stock logo
OPHLY
Ono Pharmaceutical
N/A$4.570.78N/AN/AN/AN/A7/28/2025 (Estimated)
ePlus inc. stock logo
PLUS
ePlus
$107.98M$4.0517.3517.481.805.22%11.34%6.17%8/5/2025 (Estimated)
WDEXF
OTCMKTS:WDEXF
N/AN/A0.00N/AN/AN/AN/AN/A

Latest PLUS, DSNKY, MLCPF, OPHLY, and WDEXF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q1 2026
ePlus inc. stock logo
PLUS
ePlus
$1.11N/AN/AN/A$516.70 millionN/A
5/22/2025Q4 2025
ePlus inc. stock logo
PLUS
ePlus
$0.87$0.95+$0.08$0.95$523.85 million$498.11 million
4/25/2025Q4 2025
Daiichi Sankyo Co., Ltd. - Sponsored ADR stock logo
DSNKY
Daiichi Sankyo
N/A$0.30N/A$0.30N/A$3.40 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Daiichi Sankyo Co., Ltd. - Sponsored ADR stock logo
DSNKY
Daiichi Sankyo
$0.291.32%N/A28.16%N/A
MLCPF
Medipharm Labs
N/AN/AN/AN/AN/A
Ono Pharmaceutical Co., Ltd. stock logo
OPHLY
Ono Pharmaceutical
$16.56462.48%N/A362.62%N/A
ePlus inc. stock logo
PLUS
ePlus
N/AN/AN/AN/AN/A
WDEXF
OTCMKTS:WDEXF
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Daiichi Sankyo Co., Ltd. - Sponsored ADR stock logo
DSNKY
Daiichi Sankyo
0.06
2.53
1.85
MLCPF
Medipharm Labs
N/AN/AN/A
Ono Pharmaceutical Co., Ltd. stock logo
OPHLY
Ono Pharmaceutical
N/AN/AN/A
ePlus inc. stock logo
PLUS
ePlus
0.01
1.71
1.56
WDEXF
OTCMKTS:WDEXF
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Daiichi Sankyo Co., Ltd. - Sponsored ADR stock logo
DSNKY
Daiichi Sankyo
N/A
MLCPF
Medipharm Labs
N/A
Ono Pharmaceutical Co., Ltd. stock logo
OPHLY
Ono Pharmaceutical
N/A
ePlus inc. stock logo
PLUS
ePlus
93.80%
WDEXF
OTCMKTS:WDEXF
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Daiichi Sankyo Co., Ltd. - Sponsored ADR stock logo
DSNKY
Daiichi Sankyo
17,4351.89 billionN/ANot Optionable
MLCPF
Medipharm Labs
28N/AN/ANot Optionable
Ono Pharmaceutical Co., Ltd. stock logo
OPHLY
Ono Pharmaceutical
3,761N/AN/ANot Optionable
ePlus inc. stock logo
PLUS
ePlus
2,19926.53 million25.99 millionOptionable
WDEXF
OTCMKTS:WDEXF
4N/AN/ANot Optionable

Recent News About These Companies

Zurn Elkay Water Solutions Registered Shs Aktie
Truecaller: A True Hidden Gem
Top Rohstoff-ETFs
Bayerische Motoren Werke AG ADR
Atea: Now With Small Upside (Rating Upgrade)
Cerro de Pasco Resources Inc. (CDPR.CN)
TOWTF - Tower One Wireless Corp.
CBOF - CBOA Financial, Inc.
Orkla: A Simple Thesis With A 'Buy' Rating
Ashtead: Still A Long-Term Buy
SmartCentres: A Look At The Dividend Safety

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Daiichi Sankyo stock logo

Daiichi Sankyo OTCMKTS:DSNKY

$22.03 +0.13 (+0.59%)
As of 07/11/2025 03:59 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Medipharm Labs OTCMKTS:MLCPF

$0.05 +0.00 (+3.11%)
As of 07/10/2025

MediPharm Labs Corp. primarily focuses on producing pharma-grade cannabis oil and concentrates in Canada. It also focuses on providing cannabis contract processing services to licensed producers and growers; supplying cannabis oil to companies for sale under its brand; and supplying raw materials and processing for the creation of ready-to-sell cannabis products. The company was founded in 2015 and is headquartered in Barrie, Canada.

Ono Pharmaceutical stock logo

Ono Pharmaceutical OTCMKTS:OPHLY

$3.58 +0.01 (+0.28%)
As of 07/11/2025 03:59 PM Eastern

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

ePlus stock logo

ePlus NASDAQ:PLUS

$70.27 -0.95 (-1.33%)
As of 07/11/2025 04:00 PM Eastern

ePlus inc., together with its subsidiaries, provides information technology (IT) solutions that enable organizations to optimize their IT environment and supply chain processes in the United States and internationally. It operates through two segments, Technology and Financing. The Technology segment offers hardware, perpetual and subscription software, maintenance, software assurance, and internally provided and outsourced services; managed services or infrastructure and cloud; and enhanced maintenance support, service desk, storage-as-a-service, cloud hosted and managed, and managed security services; and professional, staff augmentation, cloud consulting, consulting, and security services. The Financing segment engages in financing arrangements, such as sales-type and operating leases; loans and consumption-based financing arrangements; and underwriting, management, and disposal of IT equipment and assets. Its financing operations comprise sales, pricing, credit, contracts, accounting, and risk and asset management. This segment primarily finances IT, communication-related, and medical equipment; and industrial machinery and equipment, office furniture and general office equipment, transportation equipment, and other general business equipment directly, as well as through vendors. The company serves commercial entities, state and local governments, government contractors, healthcare, and educational institutions. The company was formerly known as MLC Holdings, Inc. and changed its name to ePlus inc. in 1999. ePlus inc. was founded in 1990 and is headquartered in Herndon, Virginia.

OTCMKTS:WDEXF OTCMKTS:WDEXF

$0.04 -0.01 (-15.45%)
As of 01/16/2020

World Class Extractions, Inc. engages in the acquisition and extraction of oils and extracts from the cannabis flower to be used for vaporizers, edibles, topicals, and beverages. It focuses on the development of proprietary technology to extract cannabinoid oils from wet or dry cannabis. The company was founded on January 25, 2018 and is headquartered in Vancouver, Canada.